Matthew C. Abernethy
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
Company network
Recorded roles and earnings-call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Neurocrine Biosciences Inc (NBIX) | Chief Financial Officer | $725,913 | $6,311,912 |
| 2024 | Neurocrine Biosciences Inc (NBIX) | Chief Financial Officer | $684,824 | $6,595,201 |
| 2023 | Neurocrine Biosciences Inc (NBIX) | Chief Financial Officer | $646,061 | $6,057,882 |
| 2022 | Neurocrine Biosciences Inc (NBIX) | Chief Financial Officer | $618,240 | $4,924,323 |
| 2021 | Neurocrine Biosciences Inc (NBIX) | Chief Financial Officer | $588,800 | $5,906,850 |
| 2020 | Neurocrine Biosciences Inc (NBIX) | Chief Financial Officer | $545,200 | $6,281,176 |
| 2019 | Neurocrine Biosciences Inc (NBIX) | Chief Financial Officer | $495,600 | $5,823,120 |
| 2018 | Neurocrine Biosciences Inc (NBIX) | Chief Financial Officer | $420,000 | $2,685,747 |
| 2017 | Neurocrine Biosciences Inc (NBIX) | Chief Financial Officer | $38,231 | $3,789,292 |
Recent activity
Earnings-call appearances and filed executive appointments or departures, newest first.